On July 3, Innovent Biologics rose 3.57% in regular trading, trading at 87.3 HKD/share, with turnover of HKD 263 million, extending its recent strong momentum.

On the news front, the company announced on June 30 a commercialization agreement with Eli Lilly for CDK4/6 inhibitor Verzenios (abemaciclib) in mainland China, under which Innovent holds exclusive rights for import, marketing, distribution, and promotion, complementing its breast cancer pipeline. Additionally, core product mazdutide passed the preliminary review for inclusion in China's national medical insurance drug catalog on June 29, marking a critical step toward reimbursement coverage. A company spokesperson noted that only the diabetes indication is eligible for insurance consideration in China.

At the sector level, biotech stocks continued their rally, with Remegen up 4.81%, 3SBio up 4.63%, BeiGene up 3.26%, SKB Bio up 3.12%, and Akeso up 2.74%, reflecting broad sector strength supporting sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)